# US 2013/0252952 A1 · 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252952 A1
- Document ID: US20130252952A1
- Status: Published application
- Kind: A1
- Application number: 13/884,149
- Filed: 2011-11-08
- Published: 2013-09-26
- Earliest claimed: 2010-11-08
- Assignees: Janssen Pharmaceuticals, Inc.
- Inventors: José Maria Cid-Núñez; Andrés Avelino Trabanco-Suárez; Juan Antonio Vega Ramiro; Daniel Oehlrich; Gary John Tresadern; Gregor James Macdonald
- Web page: https://patentgrep.com/patent/US20130252952A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/2009: {Inorganic compounds}
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/02: in which the condensed system contains two hetero rings
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

## Claims

### Claim 1

A compound of formula (I)
or a stereoisomerically isomeric form thereof,
wherein
R1 is selected from the group consisting of C1-6alkyl, (C3-8cycloalkyl)C1-3alkyl, (C1-3alkyloxy)C1-3alkyl and C1-3alkyl substituted with 1, 2 or 3 fluoro substituents;
R2 is selected from the group consisting of C1, CF3, —CN and cyclopropyl;
R3 is selected from the group consisting of hydrogen, methyl and CF3;
R4 is selected from the group consisting of hydrogen and methyl;
or R3 and R4 together with the carbon to which they are bound form a cyclopropyl ring or a carbonyl group;
L is selected from the group consisting of (L-c), (L-a), (L-b), (L-d), (L-e), (L-f) and (L-g):
wherein
R5a, R5b, R5c and R5d are each independently selected from the group consisting of phenyl; phenyl substituted with 1 or 2 substituents each independently selected from the group consisting of C1-3alkyloxy and halo; pyridinyl; pyridinyl substituted with 1 or 2 substituents each independently selected from the group consisting of C1-3alkyl, C1-3alkyloxy and halo; pyrimidinyl and pyrimidinyl substituted with 1 or 2 substituents each independently selected from the group consisting of C1-3alkyl, C1-3alkyloxy and halo;
R5e and R5f are each independently selected from the group consisting of phenyl and phenyl substituted with 1 or 2 substituents each independently selected from the group consisting of C1-3alkyloxy and halo;
R5g is selected from the group consisting of C1-3alkyl, phenyl and phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of C1-3alkyloxy and halo;
R6a, R6b, R6c, R6e, R6f and R6g are each independently selected from the group consisting of hydrogen; fluoro; C1-3alkyl; C1-3alkyl substituted with 1, 2 or 3 fluoro substituents; C1-3alkyloxy; C1-3alkyloxy substituted with 1, 2 or 3 fluoro substituents; and C3-6cycloalkyl;
R7a, R8a, R7b, R8b, R7c, R8c, R7d, R8d, R7e, R8e, R7f and R8f are each independently selected from the group consisting of hydrogen, fluoro and methyl;
R9b is selected from the group consisting of hydrogen, C1-3alkyl and C3-6cycloalkyl;
wherein
each halo is selected from the group consisting of fluoro, chloro, bromo and iodo;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, or a stereoisomeric form thereof, wherein R1 is (cyclopropyl)methyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R2 is CF3.

### Claim 4 (depends on 1)

The compound according to claim 1,
wherein R3 and R4 are both hydrogen.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein L is (L-c), wherein R5c is selected from phenyl optionally substituted with 1 or 2 fluoro substituents; R6c is selected from hydrogen or methyl and R7c and R8c are both hydrogen.

### Claim 6 (depends on 1)

The compound according to claim 1, selected from the group consisting of
3-(cyclopropylmethyl)-7-[[(3R)-3-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyridine,
3-(cyclopropylmethyl)-7-[[(3S)-3-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyridine,
3-(cyclopropylmethyl)-7-{[(3*R)-3-(2-fluorophenyl)-3-methylmorpholin-4-yl]methyl}-8-(trifluoromethyl) [1,2,4]triazolo-[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-{[(3*S)-3-(2-fluorophenyl)-3-methylmorpholin-4-yl]methyl}-8-(trifluoromethyl) [1,2,4]triazolo-[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-{[(3*R)-3-(2,4-difluorophenyl)-3-methylmorpholin-4-yl]methyl}-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine and
3-(cyclopropylmethyl)-7-{[(3*S)-3-(2,4-difluorophenyl)-3-methylmorpholin-4-yl]methyl}-8-(trifluoromethyl)-[1,2,4]triazolo [4,3-a]pyridine,
or a stereoisomeric form, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A method for the treatment of a patient for a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia comprising administering a pharmaceutically acceptable amount of the compound of claim 1 to the patient.

### Claim 10 (depends on 9)

The method according to claim 9, wherein
the psychotic disorders is selected from the group of schizophrenia, delusional disorder, schizoaffective disorder, schizophreniform disorder and substance-induced psychotic disorder;
the anxiety disorders are selected from the group of agoraphobia, generalized anxiety disorder (GAD), mixed anxiety and depression, obsessive-compulsive disorder (OCD), panic disorder, posttraumatic stress disorder (PTSD), social phobia and other phobias;
the personality disorders are selected from the group of obsessive-compulsive personality disorder and schizoid, schizotypal disorder;
the substance abuse or substance-related disorders are selected from the group of alcohol abuse, alcohol dependence, alcohol withdrawal, alcohol withdrawal delirium, alcohol-induced psychotic disorder, amphetamine dependence, amphetamine withdrawal, cocaine dependence, cocaine withdrawal, nicotine dependence, nicotine withdrawal, opioid dependence and opioid withdrawal;
the eating disorders are selected from the group of anorexia nervosa and bulimia nervosa;
the mood disorders are selected from the group of bipolar disorders (I & II), cyclothymic disorder, depression, dysthymic disorder, major depressive disorder, treatment resistant depression, bipolar depression, and substance-induced mood disorder;
the epilepsy or convulsive disorders are selected from the group of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms, epilepsy partialis continua, and other forms of epilepsy;
the cognitive disorder is selected from the group of delirium, substance-induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, dementia of the Alzheimer's type, behavioral and psychological symptoms of dementia, substance-induced persisting dementia and mild cognitive impairment.

### Claim 11 (depends on 9)

The method according to claim 9 wherein the central nervous system disorder is selected from the group of schizophrenia, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, anxiety, depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, epilepsy, attention-deficit/hyperactivity disorder, substance abuse and mixed anxiety and depression.

### Claim 12 (depends on 1)

A method for the treatment of a patient for a central nervous system disorder selected from the group consisting of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia comprising administering a pharmaceutically acceptable amount of the compound according to claim 1 in combination with a therapeutically effective amount of an orthosteric agonist of mGluR2 to the patient.

### Claim 13 (depends on 1)

A process for preparing a pharmaceutical composition comprising a pharmaceutically acceptable carrier mixed with a therapeutically effective amount of a compound as defined in claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising
(a) a compound as defined in claim 1; and
(b) an mGluR2 orthosteric agonist.
